Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Clare F Malone; Kimberly Stegmaier

doi:10.1016/j.ccell.2017.08.011

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Cancer Cell. 2017 Sep 11;32(3):271-273. doi: 10.1016/j.ccell.2017.08.011.

Authors

Clare F Malone¹, Kimberly Stegmaier²

Affiliations

¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA; Broad Institute, Cambridge, MA 02142, USA.
² Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA 02215, USA; Broad Institute, Cambridge, MA 02142, USA. Electronic address: [email protected].

PMID: 28898689
DOI: 10.1016/j.ccell.2017.08.011

Abstract

In this issue of Cancer Cell, Bosse et al. report GPC2 as a therapeutic target in neuroblastoma. They show that GPC2 is selectively expressed on the cell surface of neuroblastoma and is a dependency in this disease. Moreover, they demonstrate the therapeutic potential of an antibody-drug conjugate targeting GPC2.

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Authors

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding